The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 28 under the chairmanship of Jean-Luc Belingard and approved the consolidated financial statements for the six months ended June 30, 2015. The Statutory Auditors had performed a review of the financial statements.
Global healthcare leader educates public about sepsis dangers through Strike Out Sepsis events, webinars, grand rounds and Faces of Sepsis survivor stories during Sepsis Awareness Month
Innovative VIDAS® immunoassays system designed to answer clinical laboratories needs for automation, traceability, quality and optimized workflow
Strong growth in business €933 million in sales Up 19.5% as reported Up 8.1% like-for-like
New VIDAS® Lyme Assays Provide Differential Detection and Allow Classification of the Infection
22 June, 2015
For the Forum’s 5th edition, bioMérieux commits to support a global educational project on the fight against antimicrobial resistance recognized as a major global public health threat
2014 has been an important and decisive year for bioMérieux in more ways than one.
First White House forum to coordinate solutions to address growing public health crisis of antibiotic and antimicrobial resistance
New Campaign echoes U.S Administration’s National Strategy for Combating Antibiotic-Resistant Bacteria
Stopping sepsis through early diagnosis is a primary corporate goal of bioMérieux, Inc
